ImmunityBio (IBRX) Equity Income (2020 - 2021)
ImmunityBio (IBRX) posted quarterly Equity Income of -$442000.0 for Q2 2021, down 163.87% year-over-year from $692000.0 in Q2 2020, and down 163.87% quarter-over-quarter from $692000.0 in Q2 2020.
ImmunityBio (IBRX) Equity Income (2020 - 2021) Analysis & Trends
ImmunityBio (IBRX) has reported Equity Income for 2 consecutive years, with -$442000.0 the latest figure, recorded in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -442,000.00 |
| Jun 30, 2020 | 692,000.00 |